

Webcasted Industry Sessions

The sessions below are not included in the main event CME/CPD credit.

Product: **Dupixent**

October 19, 2024, 13:30 – 14:30

Session Description:

Emerging Perspectives on Disease Burden and Management of Children with Atopic Dermatitis – Industry Symposium Sponsored by Sanofi Atopic dermatitis (AD) is a chronic inflammatory disease with cutaneous and systemic effects that can lead to significant disease burden in children and their caregivers. This symposium will discuss diagnosis of AD in children, the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, and emerging treatment options in the management of AD in children who are candidates for systemic therapy. The overall burden of uncontrolled AD in children can lead to cumulative, life-long effects that can alter the life course of the patient, suggesting an urgency to treat AD in children.

Perla Lansang

Christine Bangert

Mark Boguniewicz

Note that this recording is intended for HCPs only.

JTNDYSUyMGhyZWYlM0QlMjJodHRwcyUzQSUyRiUyRmVhcHMyMDI0LmtlbmVzLm
NvbSUyRndwLWNvbnRlbnQlMkZ1cGxvYWRzJTJGc2l0ZXNlMkYyOSUyRjIwMjQl
MkYxMiUyRnNhbm9maV9lYXBzX2Z1bGxwcm9ncmFtX3YzXzExMDcyNC0zNjBwLm
1wNCUyMiUyMHRhcmlldCUzRCUyMl9ibGFuayUyMiUyMGlkJTNEJTIyYXBw5r
MSUyMiUyMGNsYXNzJTNEJTIyZGlzYWJsZWQlMjB0dF9idXR0b24lMjB0dF9wcm

ltYXJ5X2JldHRvbiUyMGJ0bl9wcmlltYXJ5X2NvbG9yJTIyJTNFUkVXQVRDSCUy
MFNFU1NJT04lM0MlMkZhJTNFJTBBJTNDZGl2JTIwc3R5bGULM0QlMjJ0ZXh0LW
FsaWduJTNBJTIwY2VudGVyJTNJCJTIwbWYyZ2luLXRvcCUzQSUyMDMwcHglM0IL
MjIlM0ULM0NpbnBldCUyMHR5cGULM0QlMjJjaGVja2JveCUyMiUyMGlkJTNEJT
IybXlDaGVja2JveDElMjIlM0ULMEElMjAlMjAlM0NsYWJlbCUyMGZvciUzRCUy
Mm15Q2hlY2tib3glMjIlM0VQbGVhc2ULMjBjb25maXJtJTIwdGhhdcUyMHLvdS
UyMGFyZSUyMGFuJTIwSENQJTIwYnklMjB0aWNraW5nJTIwdGhlJTIwYm94JTND
JTJGbGFIZWwLM0ULMEElM0MlMkZkaXYlM0U=JTNDc2NyaXB0JTNFJTIwY29uc3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Session programme:

- WELCOME, OBJECTIVES, AND AUDIENCE POLLING – [Perla Lansang \(Canada\)](#)
- TYPE 2 INFLAMMATION AND ITS ROLE IN AD – [Christine Bangert \(Austria\)](#)
- AD IN CHILDREN – NOT JUST A SKIN DISEASE – [Mark Boguniewicz \(United States of America\)](#)
- CURRENT AND EMERGING THERAPEUTIC OPTIONS FOR CHILDREN WITH AD – [Perla Lansang \(Canada\)](#)
- CONCLUSIONS AND Q&A

October 19, 2024, 13:30 – 14:30

Session Description:

Optimizing management of the febrile child – Can we reduce

invasive procedures, antibiotic prescriptions and hospitalizations using biomarkers? Fever without source represents a diagnostic challenge in infants and children. While existing models, rules, guidelines, and experienced clinicians demonstrate high sensitivity, their specificity is often low to modest, leading to increased invasiveness, hospitalizations, antimicrobial usage, and costs. Incorporating PCT, in conjunction with other variables, has been shown to significantly enhance specificity, thereby mitigating iatrogenic medical and social consequences. It is especially useful in infants coming to care within a few hours of fever onset.

- Learn about the diagnostic accuracy of PCT for invasive bacterial infections and its superior specificity.
- Learn about a cluster-randomized trial (4920 patients aged 6 hours to 36 months) in France for a decision-making algorithm for management of fever without source that includes PCT and its effect on antibiotic prescriptions.
- Learn what the guidelines recommend on PCT usage, how it can be implemented and the impact it can have on clinical practice as studied in Quality Improvement Initiatives

Robert H. Pantell

Alain Gervais

Christèle Gras-Le Guen

Note that this recording is intended for HCPs only.

JTNDYSUyMGhyZWYlM0QlMjJodHRwcyUzQSUyRiUyRnBsYXllci52aW1lby5jb2
0lMkZ2aWRlbyUyRjEwMjY5ODExMTUlM0ZhdXRvcGxheSUzRDElMjIlMjB0YXJn
ZXQlM0QlMjJfYmxhbmslMjIlMjBpZCUzRCUyMm15TGluazIlMjIlMjBjbGFzcy
UzRCUyMmRpc2FibGVkLTIlMjB0dF9idXR0b24lMjB0dF9wcm1tYXJ5X2JldHRv
biUyMGJ0bl9wcm1tYXJ5X2NvbG9yJTlYJTlFUKVXQVRDSCUyMFNFU1NJT04lM0

[illegible]

Session programme:

- INTRODUCTIONS – [Robert H. Pantell \(United States of America\)](#)
- CHALLENGES IN THE EARLY DIAGNOSIS OF SEVERE AND INVASIVE BACTERIAL INFECTIONS – [Alain Gervais \(Switzerland\)](#)
- REDUCING ANTIBIOTIC PRESCRIPTIONS IN PATIENTS WITH FEVER WITHOUT SOURCE: RESULTS FROM THE DIAFEVER CHILD CLUSTER RANDOMIZED TRIAL – [Christèle Gras-Le Guen \(France\)](#)
- MANAGING FEVER WITHOUT SOURCE: WHAT DO THE GUIDELINES SAY? – [Robert H. Pantell \(United States of America\)](#)
- Q&A

Note that this recording is intended for HCPs only.

JTNDYSUyMGhyZWYlM0QlMjIlMkZ3cC1jb250ZW50JTJGdXBsb2FkcyUyRnNpdG

VzJTJGMjklMkYyMDI1JTJGMDILMkZFQVBTMjAyNF9UaGVybw9GaXNoZXJTeWlw
b3NpdW1fS2V5TWVzc2FnZXNWaWRlby5tcDQlMjIlMjB0YXJnZXQlM0QlMjJfYm
xhbmslMjIlMjBpZCUzRCUyMm15TGluazMlMjIlMjBjbGFzcyUzRCUyMmRpc2Fi
bGVkLTlMlMjB0dF9idXR0b24lMjB0dF9wcmlltYXJ5X2JldHRvbiUyMGJ0bl9wcm
lltYXJ5X2NvbG9yJTIyJTNFUkVXQVRDSCUyMFNFU1NJT04lM0MlMkZhJTNFJTBB
JTNDZGl2JTIwY2VudGVyJTNcJT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